Bile acid receptors in the biliary tree: TGR5 in physiology and disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1864, Issue 4, 2018, Pages 1319-1325

  Deutschmann, Kathleen ^a   Reich, Maria ^a   Klindt, Caroline ^a   Dröge, Carola ^a   Spomer, Lina ^a   Häussinger, Dieter ^a   Keitel, Verena ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Bile acid receptor; cAMP; cholangiocarcinoma; polycystic liver disease; TGR5

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR TGR5; UNCLASSIFIED DRUG; BICARBONATE; BILE ACID; GPBAR1 PROTEIN, HUMAN; GPBAR1 PROTEIN, MOUSE;

BILE DUCT CARCINOMA; BILIARY TREE; CHOLANGIOCYTE; CHOLESTATIC HEPATITIS; HEPATOBILIARY SYSTEM; HUMAN; LIVER POLYCYSTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BILE DUCT; CELL PROLIFERATION; CHOLANGITIS; CYST; CYTOLOGY; DISEASE MODEL; EPITHELIUM CELL; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; LIVER; LIVER DISEASE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BICARBONATES; BILE ACIDS AND SALTS; BILE DUCTS; CELL PROLIFERATION; CHOLANGITIS; CYSTS; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER; LIVER DISEASES; MICE, KNOCKOUT; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85028469613     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2017.08.021     Document Type: Review

References (91)

1. Hofmann, A.F., Hagey, L.R., Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell. Mol. Life Sci. 65 (2008), 2461–2483.
2. Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A.F., Meier, P.J., The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273 (1998), 10046–10050.
3. Maillette de Buy Wenniger, L.J., Hohenester, S., Maroni, L., van Vliet, S.J., Oude Elferink, R.P., Beuers, U., The cholangiocyte glycocalyx stabilizes the 'biliary HCO3 umbrella': an integrated line of defense against toxic bile acids. Dig. Dis. 33 (2015), 397–407.
4. Mauad, T.H., van Nieuwkerk, C.M., Dingemans, K.P., Smit, J.J., Schinkel, A.H., Notenboom, R.G., van den Bergh Weerman, M.A., Verkruisen, R.P., Groen, A.K., Oude Elferink, R.P. et al., Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145 (1994), 1237–1245.
5. Becker, S., Reinehr, R., Grether-Beck, S., Eberle, A., Häussinger, D., Hydrophobic bile salts trigger ceramide formation through endosomal acidification. Biol. Chem. 388 (2007), 185–196.
6. Graf, D., Kurz, A.K., Fischer, R., Reinehr, R., Häussinger, D., Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner. Gastroenterology 122 (2002), 1411–1427.
7. Reinehr, R., Becker, S., Keitel, V., Eberle, A., Grether-Beck, S., Häussinger, D., Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 129 (2005), 2009–2031.
8. Reinehr, R., Becker, S., Wettstein, M., Häussinger, D., Involvement of the Src family kinase yes in bile salt-induced apoptosis. Gastroenterology 127 (2004), 1540–1557.
9. Patel, T., Bronk, S.F., Gores, G.J., Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J. Clin. Invest. 94 (1994), 2183–2192.
10. Beuers, U., Hohenester, S., de Buy Wenniger, L.J., Kremer, A.E., Jansen, P.L., Elferink, R.P., The biliary HCO(3)(−) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52 (2010), 1489–1496.
11. Beuers, U., Maroni, L., Elferink, R.O., The biliary HCO(3)(−) umbrella: experimental evidence revisited. Curr. Opin. Gastroenterol. 28 (2012), 253–257.
12. Hohenester, S., Wenniger, L.M., Paulusma, C.C., van Vliet, S.J., Jefferson, D.M., Elferink, R.P., Beuers, U., A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55 (2012), 173–183.
13. Keitel, V., Reich, M., Häussinger, D., TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis?. Clin Rev Allergy Immunol 48 (2015), 218–225.
14. Reich, M., Klindt, C., Deutschmann, K., Spomer, L., Häussinger, D., Keitel, V., Role of the G protein-coupled bile acid receptor TGR5 in liver damage. Dig. Dis. 35 (2017), 235–240.
15. Häussinger, D., Reinehr, R., Keitel, V., Bile acid signaling in the liver and the biliary tree. Häussinger, D., Keitel, V., Kubitz, R., (eds.) Hepatobiliary Transport in Health and Disease, 2012, DeGruyter Publishing, Place Published, 85–102.
16. Kalaany, N.Y., Mangelsdorf, D.J., LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68 (2006), 159–191.
17. Kliewer, S.A., Mangelsdorf, D.J., Bile acids as hormones: the FXR-FGF15/19 pathway. Dig. Dis. 33 (2015), 327–331.
18. Makishima, M., Okamoto, A.Y., Repa, J.J., Tu, H., Learned, R.M., Luk, A., Hull, M.V., Lustig, K.D., Mangelsdorf, D.J., Shan, B., Identification of a nuclear receptor for bile acids. Science 284 (1999), 1362–1365.
19. Modica, S., Bellafante, E., Moschetta, A., Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. Front. Biosci. (Landmark Ed.) 14 (2009), 4719–4745.
20. Parks, D.J., Blanchard, S.G., Bledsoe, R.K., Chandra, G., Consler, T.G., Kliewer, S.A., Stimmel, J.B., Willson, T.M., Zavacki, A.M., Moore, D.D., Lehmann, J.M., Bile acids: natural ligands for an orphan nuclear receptor. Science 284 (1999), 1365–1368.
21. Wang, H., Chen, J., Hollister, K., Sowers, L.C., Forman, B.M., Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 3 (1999), 543–553.
22. Gascon-Barre, M., Demers, C., Mirshahi, A., Neron, S., Zalzal, S., Nanci, A., The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 37 (2003), 1034–1042.
23. Han, S., Chiang, J.Y., Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab. Dispos. 37 (2009), 469–478.
24. Makishima, M., Lu, T.T., Xie, W., Whitfield, G.K., Domoto, H., Evans, R.M., Haussler, M.R., Mangelsdorf, D.J., Vitamin D receptor as an intestinal bile acid sensor. Science 296 (2002), 1313–1316.
25. Modica, S., Gadaleta, R.M., Moschetta, A., Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal., 8, 2010, e005.
26. Modica, S., Moschetta, A., Nuclear bile acid receptor FXR as pharmacological target: are we there yet?. FEBS Lett. 580 (2006), 5492–5499.
27. Pellicciari, R., Costantino, G., Camaioni, E., Sadeghpour, B.M., Entrena, A., Willson, T.M., Fiorucci, S., Clerici, C., Gioiello, A., Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J. Med. Chem. 47 (2004), 4559–4569.
28. Xia, X., Jung, D., Webb, P., Zhang, A., Zhang, B., Li, L., Ayers, S.D., Gabbi, C., Ueno, Y., Gustafsson, J.A., Alpini, G., Moore, D.D., Lesage, G.D., Liver X receptor beta and peroxisome proliferator-activated receptor delta regulate cholesterol transport in murine cholangiocytes. Hepatology 56 (2012), 2288–2296.
29. Staudinger, J.L., Goodwin, B., Jones, S.A., Hawkins-Brown, D., MacKenzie, K.I., LaTour, A., Liu, Y., Klaassen, C.D., Brown, K.K., Reinhard, J., Willson, T.M., Koller, B.H., Kliewer, S.A., The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 3369–3374.
30. Xie, W., Radominska-Pandya, A., Shi, Y., Simon, C.M., Nelson, M.C., Ong, E.S., Waxman, D.J., Evans, R.M., An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 3375–3380.
31. Cheng, K., Chen, Y., Zimniak, P., Raufman, J.P., Xiao, Y., Frucht, H., Functional interaction of lithocholic acid conjugates with M3 muscarinic receptors on a human colon cancer cell line. Biochim. Biophys. Acta 1588 (2002), 48–55.
32. Raufman, J.P., Chen, Y., Cheng, K., Compadre, C., Compadre, L., Zimniak, P., Selective interaction of bile acids with muscarinic receptors: a case of molecular mimicry. Eur. J. Pharmacol. 457 (2002), 77–84.
33. Raufman, J.P., Chen, Y., Zimniak, P., Cheng, K., Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists. Pharmacology 65 (2002), 215–221.
34. Sheikh Abdul Kadir, S.H., Miragoli, M., Abu-Hayyeh, S., Moshkov, A.V., Xie, Q., Keitel, V., Nikolaev, V.O., Williamson, C., Gorelik, J., Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes. PLoS One, 5, 2010, e9689.
35. Alvaro, D., Alpini, G., Jezequel, A.M., Bassotti, C., Francia, C., Fraioli, F., Romeo, R., Marucci, L., Le Sage, G., Glaser, S.S., Benedetti, A., Role and mechanisms of action of acetylcholine in the regulation of rat cholangiocyte secretory functions. J. Clin. Invest. 100 (1997), 1349–1362.
36. Wang, Y., Aoki, H., Yang, J., Peng, K., Liu, R., Li, X., Qiang, X., Sun, L., Gurley, E.C., Lai, G., Zhang, L., Liang, G., Nagahashi, M., Takabe, K., Pandak, W.M., Hylemon, P.B., Zhou, H., The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice. Hepatology 65 (2017), 2005–2018.
37. Nagahashi, M., Yuza, K., Hirose, Y., Nakajima, M., Ramanathan, R., Hait, N.C., Hylemon, P.B., Zhou, H., Takabe, K., Wakai, T., The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. J. Lipid Res. 57 (2016), 1636–1643.
38. Liu, R., Li, X., Qiang, X., Luo, L., Hylemon, P.B., Jiang, Z., Zhang, L., Zhou, H., Taurocholate induces cyclooxygenase-2 expression via the sphingosine 1-phosphate receptor 2 in a human cholangiocarcinoma cell line. J. Biol. Chem. 290 (2015), 30988–31002.
39. Liu, R., Zhao, R., Zhou, X., Liang, X., Campbell, D.J., Zhang, X., Zhang, L., Shi, R., Wang, G., Pandak, W.M., Sirica, A.E., Hylemon, P.B., Zhou, H., Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 60 (2014), 908–918.
40. Keitel, V., Häussinger, D., TGR5 in the biliary tree. Dig. Dis. 29 (2011), 45–47.
41. Keitel, V., Häussinger, D., Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin. Res. Hepatol. Gastroenterol. 36 (2012), 412–419.
42. Keitel, V., Häussinger, D., TGR5 in cholangiocytes. Curr. Opin. Gastroenterol. 29 (2013), 299–304.
43. Keitel, V., Ullmer, C., Häussinger, D., The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol. Chem. 391 (2010), 785–789.
44. Masyuk, A.I., Huang, B.Q., Radtke, B.N., Gajdos, G.B., Splinter, P.L., Masyuk, T.V., Gradilone, S.A., LaRusso, N.F., Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 304 (2013), G1013–1024.
45. Reich, M., Deutschmann, K., Sommerfeld, A., Klindt, C., Kluge, S., Kubitz, R., Ullmer, C., Knoefel, W.T., Herebian, D., Mayatepek, E., Häussinger, D., Keitel, V., TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut 65 (2016), 487–501.
46. Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., Hinuma, S., Fujisawa, Y., Fujino, M., A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 278 (2003), 9435–9440.
47. Maruyama, T., Miyamoto, Y., Nakamura, T., Tamai, Y., Okada, H., Sugiyama, E., Nakamura, T., Itadani, H., Tanaka, K., Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun. 298 (2002), 714–719.
48. Sato, H., Macchiarulo, A., Thomas, C., Gioiello, A., Une, M., Hofmann, A.F., Saladin, R., Schoonjans, K., Pellicciari, R., Auwerx, J., Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem. 51 (2008), 1831–1841.
49. Studer, E., Zhou, X., Zhao, R., Wang, Y., Takabe, K., Nagahashi, M., Pandak, W.M., Dent, P., Spiegel, S., Shi, R., Xu, W., Liu, X., Bohdan, P., Zhang, L., Zhou, H., Hylemon, P.B., Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 55 (2012), 267–276.
50. Keitel, V., Görg, B., Bidmon, H.J., Zemtsova, I., Spomer, L., Zilles, K., Häussinger, D., The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 58 (2010), 1794–1805.
51. Keitel, V., Spomer, L., Marin, J.J., Williamson, C., Geenes, V., Kubitz, R., Häussinger, D., Macias, R.I., Effect of maternal cholestasis on TGR5 expression in human and rat placenta at term. Placenta 34 (2013), 810–816.
52. Keitel, V., Donner, M., Winandy, S., Kubitz, R., Häussinger, D., Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem. Biophys. Res. Commun. 372 (2008), 78–84.
53. Keitel, V., Reinehr, R., Gatsios, P., Rupprecht, C., Görg, B., Selbach, O., Häussinger, D., Kubitz, R., The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45 (2007), 695–704.
54. Keitel, V., Cupisti, K., Ullmer, C., Knoefel, W.T., Kubitz, R., Häussinger, D., The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50 (2009), 861–870.
55. Lavoie, B., Balemba, O.B., Godfrey, C., Watson, C.A., Vassileva, G., Corvera, C.U., Nelson, M.T., Mawe, G.M., Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J. Physiol. 588 (2010), 3295–3305.
56. Li, T., Holmstrom, S.R., Kir, S., Umetani, M., Schmidt, D.R., Kliewer, S.A., Mangelsdorf, D.J., The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol. Endocrinol. 25 (2011), 1066–1071.
57. Pellicciari, R., Gioiello, A., Macchiarulo, A., Thomas, C., Rosatelli, E., Natalini, B., Sardella, R., Pruzanski, M., Roda, A., Pastorini, E., Schoonjans, K., Auwerx, J., Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J. Med. Chem. 52 (2009), 7958–7961.
58. Briere, D.A., Ruan, X., Cheng, C.C., Siesky, A.M., Fitch, T.E., Dominguez, C., Sanfeliciano, S.G., Montero, C., Suen, C.S., Xu, Y., Coskun, T., Michael, M.D., Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice. PLoS One, 10, 2015, e0136873.
59. Duan, H., Ning, M., Chen, X., Zou, Q., Zhang, L., Feng, Y., Zhang, L., Leng, Y., Shen, J., Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists. J. Med. Chem. 55 (2012), 10475–10489.
60. Vassileva, G., Golovko, A., Markowitz, L., Abbondanzo, S.J., Zeng, M., Yang, S., Hoos, L., Tetzloff, G., Levitan, D., Murgolo, N.J., Keane, K., Davis, H.R. Jr., Hedrick, J., Gustafson, E.L., Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem. J. 398 (2006), 423–430.
61. Pean, N., Doignon, I., Garcin, I., Besnard, A., Julien, B., Liu, B., Branchereau, S., Spraul, A., Guettier, C., Humbert, L., Schoonjans, K., Rainteau, D., Tordjmann, T., The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology 58 (2013), 1451–1460.
62. Franke, A., Balschun, T., Karlsen, T.H., Sventoraityte, J., Nikolaus, S., Mayr, G., Domingues, F.S., Albrecht, M., Nothnagel, M., Ellinghaus, D., Sina, C., Onnie, C.M., Weersma, R.K., Stokkers, P.C., Wijmenga, C., Gazouli, M., Strachan, D., McArdle, W.L., Vermeire, S., Rutgeerts, P., Rosenstiel, P., Krawczak, M., Vatn, M.H., Mathew, C.G., Schreiber, S., Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40 (2008), 1319–1323.
63. Hov, J.R., Keitel, V., Laerdahl, J.K., Spomer, L., Ellinghaus, E., ElSharawy, A., Melum, E., Boberg, K.M., Manke, T., Balschun, T., Schramm, C., Bergquist, A., Weismuller, T., Gotthardt, D., Rust, C., Henckaerts, L., Onnie, C.M., Weersma, R.K., Sterneck, M., Teufel, A., Runz, H., Stiehl, A., Ponsioen, C.Y., Wijmenga, C., Vatn, M.H., I.S. Group, Stokkers, P.C., Vermeire, S., Mathew, C.G., Lie, B.A., Beuers, U., Manns, M.P., Schreiber, S., Schrumpf, E., Häussinger, D., Franke, A., Karlsen, T.H., Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One, 5, 2010, e12403.
64. Hov, J.R., Keitel, V., Schrumpf, E., Häussinger, D., Karlsen, T.H., TGR5 sequence variation in primary sclerosing cholangitis. Dig. Dis. 29 (2011), 78–84.
65. Masyuk, T.V., Masyuk, A.I., LaRusso, N.F., TGR5 in the Cholangiociliopathies. Dig. Dis. 33 (2015), 420–425.
66. Larusso, N.F., Masyuk, T.V., Hogan, M.C., Polycystic liver disease: the benefits of targeting cAMP. Clin. Gastroenterol. Hepatol. 14 (2016), 1031–1034.
67. Masyuk, T.V., Masyuk, A.I., Lorenzo Pisarello, M., Howard, B.N., Huang, B.Q., Lee, P.Y., Fung, X., Sergienko, E., Ardesky, R.J., Chung, T.D., Pinkerton, A.B., LaRusso, N.F., TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases via cAMP/Galphas signaling. Hepatology, 2017, 10.1002/hep.29284 (Epub ahead of print).
68. Perugorria, M.J., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J.J., Bujanda, L., Banales, J.M., Bile acids in polycystic liver diseases: triggers of disease progression and potential solution for treatment. Dig. Dis. 35 (2017), 275–281.
69. Lozano, E., Sanchez-Vicente, L., Monte, M.J., Herraez, E., Briz, O., Banales, J.M., Marin, J.J., Macias, R.I., Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol. Cancer Res. 12 (2014), 91–100.
70. Dai, J., Wang, H., Dong, Y., Zhang, Y., Wang, J., Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway. Cancer Investig. 31 (2013), 111–120.
71. Dai, J., Wang, H., Shi, Y., Dong, Y., Zhang, Y., Wang, J., Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J. Hematol. Oncol., 4, 2011, 41.
72. Xu, L., Hausmann, M., Dietmaier, W., Kellermeier, S., Pesch, T., Stieber-Gunckel, M., Lippert, E., Klebl, F., Rogler, G., Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer, 10, 2010, 302.
73. Amonyingcharoen, S., Suriyo, T., Thiantanawat, A., Watcharasit, P., Satayavivad, J., Taurolithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway. Int. J. Oncol. 46 (2015), 2317–2326.
74. Jung, D., York, J.P., Wang, L., Yang, C., Zhang, A., Francis, H.L., Webb, P., McKeehan, W.L., Alpini, G., Lesage, G.D., Moore, D.D., Xia, X., FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway. Pflugers Arch. 466 (2014), 1011–1019.
75. Kennedy, L., Baker, K., Hodges, K., Graf, A., Venter, J., Hargrove, L., Harris, R., Harnish, E., Meng, F., Francis, H., Dysregulation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth. Dig. Liver Dis. 45 (2013), 316–322.
76. Perino, A., Pols, T.W., Nomura, M., Stein, S., Pellicciari, R., Schoonjans, K., TGR5 reduces macrophage migration through mTOR-induced C/EBPbeta differential translation. J. Clin. Invest. 124 (2014), 5424–5436.
77. Perino, A., Schoonjans, K., TGR5 and immunometabolism: insights from physiology and pharmacology. Trends Pharmacol. Sci. 36 (2015), 847–857.
78. Pols, T.W., Nomura, M., Harach, T., Lo Sasso, G., Oosterveer, M.H., Thomas, C., Rizzo, G., Gioiello, A., Adorini, L., Pellicciari, R., Auwerx, J., Schoonjans, K., TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 14 (2011), 747–757.
79. Wang, Y.D., Chen, W.D., Yu, D., Forman, B.M., Huang, W., The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54 (2011), 1421–1432.
80. Cao, W., Tian, W., Hong, J., Li, D., Tavares, R., Noble, L., Moss, S.F., Resnick, M.B., Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am. J. Physiol. Gastrointest. Liver Physiol. 304 (2013), G322–327.
81. Hong, J., Behar, J., Wands, J., Resnick, M., Wang, L.J., DeLellis, R.A., Lambeth, D., Souza, R.F., Spechler, S.J., Cao, W., Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 59 (2010), 170–180.
82. Casaburi, I., Avena, P., Lanzino, M., Sisci, D., Giordano, F., Maris, P., Catalano, S., Morelli, C., Ando, S., Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle 11 (2012), 2699–2710.
83. Alemi, F., Kwon, E., Poole, D.P., Lieu, T., Lyo, V., Cattaruzza, F., Cevikbas, F., Steinhoff, M., Nassini, R., Materazzi, S., Guerrero-Alba, R., Valdez-Morales, E., Cottrell, G.S., Schoonjans, K., Geppetti, P., Vanner, S.J., Bunnett, N.W., Corvera, C.U., The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123 (2013), 1513–1530.
84. Desai, M.S., Shabier, Z., Taylor, M., Lam, F., Thevananther, S., Kosters, A., Karpen, S.J., Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis. Hepatology 51 (2010), 2097–2107.
85. Fryer, R.M., Ng, K.J., Nodop Mazurek, S.G., Patnaude, L., Skow, D.J., Muthukumarana, A., Gilpin, K.E., Dinallo, R.M., Kuzmich, D., Lord, J., Sanyal, S., Yu, H., Harcken, C., Cerny, M.A., Hickey, E.R., Modis, L.K., G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism. J. Pharmacol. Exp. Ther. 348 (2014), 421–431.
86. Sampaziotis, F., de Brito, M.C., Madrigal, P., Bertero, A., Saeb-Parsy, K., Soares, F.A.C., Schrumpf, E., Melum, E., Karlsen, T.H., Bradley, J.A., Gelson, W.T., Davies, S., Baker, A., Kaser, A., Alexander, G.J., Hannan, N.R.F., Vallier, L., Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Nat. Biotechnol. 33 (2015), 845–852.
87. Sampaziotis, F., Justin, A.W., Tysoe, O.C., Sawiak, S., Godfrey, E.M., Upponi, S.S., Gieseck, R.L. 3rd, de Brito, M.C., Berntsen, N.L., Gomez-Vazquez, M.J., Ortmann, D., Yiangou, L., Ross, A., Bargehr, J., Bertero, A., Zonneveld, M.C.F., Pedersen, M.T., Pawlowski, M., Valestrand, L., Madrigal, P., Georgakopoulos, N., Pirmadjid, N., Skeldon, G.M., Casey, J., Shu, W., Materek, P.M., Snijders, K.E., Brown, S.E., Rimland, C.A., Simonic, I., Davies, S.E., Jensen, K.B., Zilbauer, M., Gelson, W.T.H., Alexander, G.J., Sinha, S., Hannan, N.R.F., Wynn, T.A., Karlsen, T.H., Melum, E., Markaki, A.E., Saeb-Parsy, K., Vallier, L., Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nat. Med. 23 (2017), 954–963.
88. De Assuncao, T.M., Sun, Y., Jalan-Sakrikar, N., Drinane, M.C., Huang, B.Q., Li, Y., Davila, J.I., Wang, R., O'Hara, S.P., Lomberk, G.A., Urrutia, R.A., Ikeda, Y., Huebert, R.C., Development and characterization of human-induced pluripotent stem cell-derived cholangiocytes. Lab. Investig. 95 (2015), 684–696.
89. Li, B., Dorrell, C., Canaday, P.S., Pelz, C., Haft, A., Finegold, M., Grompe, M., Adult mouse liver contains two distinct populations of cholangiocytes. Stem Cell Rep. 9 (2017), 478–489.
90. Ogawa, M., Ogawa, S., Bear, C.E., Ahmadi, S., Chin, S., Li, B., Grompe, M., Keller, G., Kamath, B.M., Ghanekar, A., Directed differentiation of cholangiocytes from human pluripotent stem cells. Nat. Biotechnol. 33 (2015), 853–861.
91. Zhang, O., Hsu, F.F., Xu, W., Pawlowic, M., Zhang, K., Sphingosine kinase A is a pleiotropic and essential enzyme for Leishmania survival and virulence. Mol. Microbiol. 90 (2013), 489–501.